Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Cancer Cell. 2012 Feb 14;21(2):181-95. doi: 10.1016/j.ccr.2011.12.026.
Lymphatic metastasis is facilitated by lymphangiogenic growth factors VEGF-C and VEGF-D that are secreted by some primary tumors. We identified regulation of PGDH, the key enzyme in prostaglandin catabolism, in endothelial cells of collecting lymphatics, as a key molecular change during VEGF-D-driven tumor spread. The VEGF-D-dependent regulation of the prostaglandin pathway was supported by the finding that collecting lymphatic vessel dilation and subsequent metastasis were affected by nonsteroidal anti-inflammatory drugs (NSAIDs), known inhibitors of prostaglandin synthesis. Our data suggest a control point for cancer metastasis within the collecting lymphatic endothelium, which links VEGF-D/VEGFR-2/VEGFR-3 and the prostaglandin pathways. Collecting lymphatics therefore play an active and important role in metastasis and may provide a therapeutic target to restrict tumor spread.
淋巴转移是由一些原发性肿瘤分泌的淋巴管生成生长因子 VEGF-C 和 VEGF-D 促进的。我们发现,在 VEGF-D 驱动的肿瘤扩散过程中,作为关键的分子变化,PGDH(前列腺素分解代谢的关键酶)在收集淋巴管的内皮细胞中的表达受到调节。非甾体抗炎药(NSAIDs),即已知的前列腺素合成抑制剂,能够扩张收集淋巴管并促进随后的转移,这一发现支持了前列腺素通路在 VEGF-D 依赖性调节中的作用。我们的数据表明,在收集淋巴管内皮细胞中存在一个控制癌症转移的关键点,它将 VEGF-D/VEGFR-2/VEGFR-3 和前列腺素途径联系起来。因此,收集淋巴管在转移中发挥着积极而重要的作用,并可能为限制肿瘤扩散提供治疗靶点。